SAB Capex To Depreciation from 2010 to 2024

SABSW Stock  USD 0.07  0  5.75%   
SAB Biotherapeutics Capex To Depreciation yearly trend continues to be fairly stable with very little volatility. Capex To Depreciation will likely drop to 0.05 in 2024. Capex To Depreciation is the ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets. View All Fundamentals
 
Capex To Depreciation  
First Reported
2010-12-31
Previous Quarter
0.05264063
Current Value
0.05
Quarterly Volatility
5.7192692
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check SAB Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among SAB Biotherapeutics' main balance sheet or income statement drivers, such as Interest Income of 80.1 K, Depreciation And Amortization of 3.9 M or Interest Expense of 289.4 K, as well as many indicators such as Price To Sales Ratio of 16.12, Dividend Yield of 0.0 or PTB Ratio of 0.7. SAB financial statements analysis is a perfect complement when working with SAB Biotherapeutics Valuation or Volatility modules.
  
Check out the analysis of SAB Biotherapeutics Correlation against competitors.
For more information on how to buy SAB Stock please use our How to Invest in SAB Biotherapeutics guide.

Latest SAB Biotherapeutics' Capex To Depreciation Growth Pattern

Below is the plot of the Capex To Depreciation of SAB Biotherapeutics over the last few years. It is the ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets. SAB Biotherapeutics' Capex To Depreciation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in SAB Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
Capex To Depreciation10 Years Trend
Pretty Stable
   Capex To Depreciation   
       Timeline  

SAB Capex To Depreciation Regression Statistics

Arithmetic Mean3.69
Geometric Mean1.63
Coefficient Of Variation154.89
Mean Deviation3.38
Median1.88
Standard Deviation5.72
Sample Variance32.71
Range23.1755
R-Value0.23
Mean Square Error33.34
R-Squared0.05
Significance0.41
Slope0.30
Total Sum of Squares457.94

SAB Capex To Depreciation History

2024 0.05
2023 0.0526
2021 6.62
2020 23.23

About SAB Biotherapeutics Financial Statements

SAB Biotherapeutics investors use historical fundamental indicators, such as SAB Biotherapeutics' Capex To Depreciation, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in SAB Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capex To Depreciation 0.05  0.05 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for SAB Stock Analysis

When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.